Fatigue, headache, or mild dizziness may also occur, particularly during the early stages of therapy
Highlights: GLP-1 receptor drugs cause meaningful and sustained weight loss compared to placebo Industry funding raises concerns over potential bias and long-term safety gaps Independent and equitable access to these medications remains a global priority questions persist about potential biases and long-term impacts
variable purity, stability concerns, no reliable regulation or third-party verification for most users
External resources Efficacy and safety of retatrutide: systematic review and meta-analysis (PMC) Triple hormone receptor agonist retatrutide for obesity: Phase 2 trial (NEJM) Tesamorelin clinical pharmacology and safety (NCBI LiverTox) Safety and metabolic effects of tesamorelin in type 2 diabetes (PMC) Tesamorelin prescribing information and side effects (Mayo Clinic) Retatrutide for metabolic dysfunction-associated steatotic liver disease (Nature Medicine) For researchers serious about optimizing their peptide protocols, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, proven protocols, and a community of thousands who have navigated these exact questions
2.5 Ethical consideration Considering that all ICSRs collected in the EV database are anonymized and do not include any information that could identify the patient, Ethics Committee approval was deemed unnecessary
In a perfect world, all waste would be recycled or beneficially used and the earth would be powered purely by renewable energy, but were not there yet